We are live on ! Find out more
ALKS icon

Alkermes

48.90 USD
-0.26
0.53%
At close Updated Aug 27, 4:00 PM EDT
Pre-market
After hours
48.90
0.00
0%
1 day
-0.53%
5 days
1.77%
1 month
-7.26%
3 months
28.38%
6 months
62.46%
Year to date
73.04%
1 year
67.18%
5 years
57.18%
10 years
9.96%
 

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 2,050

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 52.2%
Neutral 47.8%
Negative 0%
Positive
Zacks Investment Research
16 hours ago
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Neutral
Business Wire
3 days ago
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,.
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Positive
Zacks Investment Research
15 days ago
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Neutral
Seeking Alpha
1 month ago
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
Positive
MarketBeat
1 month ago
Alkermes Q2 Earnings Call Highlights
Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following the company's acquisition of Avadel. The company also highlighted progress across its orexin development pipeline and reiterated most of its full-year financial outlook.
Alkermes Q2 Earnings Call Highlights
Neutral
Zacks Investment Research
1 month ago
Alkermes (ALKS) Reports Break-Even Earnings for Q2
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago.
Alkermes (ALKS) Reports Break-Even Earnings for Q2
Neutral
Business Wire
1 month ago
Alkermes plc Reports Second Quarter 2026 Financial Results
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast ma.
Alkermes plc Reports Second Quarter 2026 Financial Results
Positive
Zacks Investment Research
1 month ago
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Price charts implemented using Lightweight Charts™